UTHR's ralinepag NDA receives FDA acceptance, with a 2027 decision ahead as positive phase III data

ADVANCE OUTCOMES presentations include an analysis showing that ralinepag achieved clinical improvem

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that f

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C--(BUSINESS WIRE)--United Therapeutics Corporation (

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation

Allworth Financial LP acquired a new position in shares of United Therapeutics Corporation (NASDAQ:

United Therapeutics completes enrollment in its phase III study evaluating Tyvaso for an additional

Approximately 200,000 patients in the United States have PPF, with limited treatment optionsTopline

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation

United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 sh

Atwood and Palmer Inc. cut its stake in shares of United Therapeutics Corporation (NASDAQ: UTHR) by

RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and

UTHR tops Q2 EPS estimates, misses revenues, while advancing Tyvaso and ralinepag programs that resh

United Therapeutics NASDAQ: UTHR reported second-quarter 2026 revenue of approximately $783 million,

United Therapeutics Corporation (UTHR) Q2 2026 Earnings Call Transcript

Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business perform

United Therapeutics (UTHR) came out with quarterly earnings of $7.27 per share, beating the Zacks Co

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation

Investors interested in Medical - Drugs stocks are likely familiar with United Therapeutics (UTHR) a

The long-term, pivotal, phase 3 ADVANCE OUTCOMES study of ralinepag in predominantly pre-treated pat

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation

9,500 shares were disposed of for ~$5.0 million based on a weighted average execution price of $530.

Liquidia's Yutrepia launch is fueling rapid growth, outperforming United Therapeutics on estimates a

Atika Capital Management LLC purchased a new stake in shares of United Therapeutics Corporation (NAS

JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and r

B of A Securities analyst Greg Harrison maintains United Therapeutics (NASDAQ:UTHR) with a Neutra

The flights carried manufactured organs, being developed by United TherapeuticsThe flights are also

RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and

United Therapeutics (UTHR) acquires Thymmune Therapeutics for $140M upfront, with up to $160M in mil

United Therapeutics Corporation (Nasdaq: UTHR) announced today it has acquired Thymmune Therapeutics

United Therapeutics received FDA approval for LungFX, a device designed to expand donor lung use in

The pivotal TETON-1 phase 3 study of nebulized Tyvaso® (treprostinil) Inhalation Solution in idiopat

U.S. stock futures down on Monday. Focus on Baidu, Brady, United Therapeutics for earnings. XP and R

United Therapeutics Corporation (NASDAQ:UTHR), a public benefit corporation, today announced that th

Through the collaboration, Varda and United Therapeutics will conduct pharmaceutical processing of s

Presentations of results from the positive TETON phase 3 pivotal studies of inhaled treprostinil in

RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and

Wells Fargo analyst Benjamin Burnett upgrades United Therapeutics (NASDAQ:UTHR) from Equal-Weight

The formulation is being developed in collaboration with United Therapeutics Corporation United Ther

United Therapeutics (NASDAQ:UTHR) reported quarterly earnings of $5.82 per share which missed the an

An interim analysis of the PHINDER study identifies non-invasive measures that may facilitate earlie

Morgan Stanley analyst Terence Flynn maintains United Therapeutics (NASDAQ:UTHR) with a Equal-Wei

HC Wainwright & Co. analyst Andrew S. Fein maintains United Therapeutics (NASDAQ:UTHR) with a

Wells Fargo analyst Benjamin Burnett maintains United Therapeutics (NASDAQ:UTHR) with a Equal-Wei

B of A Securities analyst Greg Harrison maintains United Therapeutics (NASDAQ:UTHR) with a Neutra

U.S. equity markets snap a five-week slide on Monday, bouncing off seven-month lows after President

Dow Jones index up 400 points. IQIYI rose on buyback & HK listing. CODI, UTHR, SGML, CLMT, TRON,